Beta Bionics (NASDAQ:BBNX) & AngioDynamics (NASDAQ:ANGO) Financial Comparison

AngioDynamics (NASDAQ:ANGO) and Beta Bionics (NASDAQ:BBNX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Profitability

This table compares AngioDynamics and Beta Bionics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AngioDynamics	-10.12%	-4.49%	-2.96%
Beta Bionics	-61.31%	-26.30%	-23.25%

Insider and Institutional Ownership

89.4% of AngioDynamics shares are held by institutional investors. 6.0% of AngioDynamics shares are held by insiders. Comparatively, 5.3% of Beta Bionics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for AngioDynamics and Beta Bionics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	1	1	2	1	2.60
Beta Bionics	1	4	9	1	2.67

AngioDynamics presently has a consensus price target of $19.00, suggesting a potential upside of 53.72%. Beta Bionics has a consensus price target of $24.00, suggesting a potential upside of 25.26%. Given AngioDynamics’ higher probable upside, equities analysts plainly believe AngioDynamics is more favorable than Beta Bionics.

Valuation and Earnings

This table compares AngioDynamics and Beta Bionics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$320.17 million	1.62	-$36.74 million	($0.78)	-15.85
Beta Bionics	$100.25 million	8.60	-$73.20 million	($1.65)	-11.61

AngioDynamics has higher revenue and earnings than Beta Bionics. AngioDynamics is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

AngioDynamics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Beta Bionics has a beta of 3.39, suggesting that its stock price is 239% more volatile than the S&P 500.

Summary

AngioDynamics beats Beta Bionics on 9 of the 13 factors compared between the two stocks.

About AngioDynamics

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.